Colucid Pharmaceuticals IPO Research Information

Colucid Pharmaceuticals IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Colucid Pharmaceuticals, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Colucid Pharmaceuticals	CLCD - NASDAQ	$13.00-$15.00	$10.00	$8.50	5.5 million	5/6/2015
Underwriter(s): Piper Jaffray, Stifel
Co-Manager(s): William Blair, Ladenburg Thalmann
Industry: Health Care
Filing(s): Filed 2015-03-30 Terms Added 2015-04-20

Colucid Pharmaceuticals Quote & Chart - Click for current quote - CLCD

About Colucid Pharmaceuticals (adapted from Colucid Pharmaceuticals prospectus):
They are a Phase 3 clinical-stage biopharmaceutical company that is developing an innovative and proprietary small molecule for the acute treatment of migraine headaches.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "CLCD" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.